We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.
Prof Paresh Vyas is leading a new clincal trial at Oxford's Churchill Hospital which plans to study the safety of a new experimental drug to treat a form of leukaemia, called Acute Myeloid Leukaemia (AML).